Pharmaceutical

Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

Tabuk obatined rights to commercialise Formosacs l'obetasol propionate ophthalmic suspension 0.05% for inflammation after ocular surgery.

May 11, 2024 - 04:00
Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension
Tabuk obatined rights to commercialise Formosacs l'obetasol propionate ophthalmic suspension 0.05% for inflammation after ocular surgery.
Read the original article

Tags:

Previous Article

Shionogi secures licence for Maze’s Pompe disease treatment

Next Article

Four ways the vaccine rush will define infectious disease trends for CROs in 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Nobel Prize, in a rarity, celebrates a fruitful and durable partnership

STAT+: Nobel Prize, in a rarity, celebrates a fruitful ...

Oct 2, 2023

AlphaFold developers and eye scan inventors among Lasker Award winners for 2023

AlphaFold developers and eye scan inventors among Laske...

Sep 22, 2023

Sterilisation Solutions, Equipment and Services for the Pharmaceutical Industry

Sterilisation Solutions, Equipment and Services for the...

Oct 2, 2024